导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -3.73% | 3273/4773 |
| 近一周 | -2.47% | 3914/5465 |
| 近一月 | -1.89% | 1363/5421 |
| 近一季 | -3.99% | 1730/5231 |
| 近半年 | -7.74% | 3410/4920 |
| 近一年 | -6.84% | 3227/4394 |
| 近两年 | 43.92% | 1730/2954 |
| 近三年 | 23.65% | 1354/2253 |
| 成立以来 | 46.86% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-1.19% 2170/4961 |
-1.66% 3358/5312 |
- - |
- - |
| 2025 | 17.79% 2352/4813 |
3.73% 1045/3635 |
9.89% 269/4076 |
5.55% 3582/4524 |
-2.10% 3092/4813 |
| 2024 | 17.95% 634/3463 |
4.95% 413/2808 |
-2.96% 1280/3014 |
14.54% 1960/3129 |
1.11% 1119/3463 |
| 2023 | -3.40% 636/2656 |
2.62% 1327/2280 |
2.73% 125/2385 |
-2.31% 660/2515 |
-6.20% 1663/2655 |
| 2022 | -13.28% 322/2207 |
-10.33% 390/1919 |
1.87% 1409/2016 |
-10.72% 444/2113 |
6.34% 368/2208 |
| 2021 | 14.37% 336/1822 |
4.42% 149/1255 |
9.77% 522/1330 |
-5.06% 773/1466 |
5.09% 305/1822 |
| 2020 | - - |
- - |
- - |
- - |
5.32% 790/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 华夏中证浙江国资创新发展ETF VS. 长安沪深300非周期A(740101) |